

# Acasti Pharma Inc

08:52 13 Jan 2020

## Acasti Pharma says further analysis underway after TRILOGY 1 topline results show unexpected placebo effect

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) says further analysis is underway after topline results from its TRILOGY 1 trial for lead product CaPre did not reach statistical significance due to the unusually large placebo effect.

The biotech is developing the krill-oil derived drug called CaPre to treat hypertriglyceridemia (high levels of triglycerides in the blood), which is known to contribute to heart disease and the findings of this Phase III trial have been much anticipated.

READ: Acasti Pharma shares on the move, expects to report TRILOGY 1 results of CaPre trial in January

Both the placebo and CaPre study groups saw significant reductions in triglycerides within the first four weeks from baseline, the firm said.

Although the difference at 12 and 26 weeks was in favor of CaPre, due to the unexpectedly large placebo response, TRILOGY 1 did not reach statistical significance, the firm said in a statement.

"While we are encouraged by the magnitude of reduction in triglyceride levels seen among patients receiving CaPre, the large placebo effect was completely unexpected, and was about double what was seen in all other therapeutic OM3 hypertriglyceridemia trials," noted Jan D'Alvise, the president and CEO of Acasti.

Several hypotheses are being investigated now by the group's clinical team, and by our CRO and Dr. Dariush Mozaffarian, the principal investigator for the study, she added.

"These avenues of investigation are being carefully and rigorously pursued, and we are moving as quickly as possible to try to gain understanding and insight into the large and unexpected placebo response seen in TRILOGY 1.

"The company will continue to provide updates on this investigation, as well as topline results for TRILOGY 2 as we get them, to be followed by all secondary and exploratory endpoints for TRILOGY 1 and 2 once the TRILOGY 2 study is completed and fully analyzed."

Acasti told investors that a full audit of enrolling sites, including review of all raw data and records from patients taking both CaPre and placebo, will be conducted to identify a possible root cause of this 'unprecedented' placebo effect.


This is likely to take at least several weeks, with an outcome expected by the end of February, it said.

Notably, due to additional resources now going toward TRILOGY 1, there could be a small delay of a couple of weeks in reporting topline results for TRILOGY 2 to mid-February 2020.

**Price:** 0.61

**Market Cap:** \$55.03 m

### 1 Year Share Price Graph



February 2019 August 2019 February 2020

### Share Information

**Code:** ACST

**Listing:** TSX-V

<b>52 week</b>	<b>High</b>	<b>Low</b>
	4.05	0.56

**Sector:** Pharma & Biotech

**Website:** [www.acastipharma.com](http://www.acastipharma.com)

### Company Synopsis:

*Acasti is a biopharmaceutical innovator focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. Omega-3 fatty acids have extensive clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia.*

action@proactiveinvestors.com

### Key secondary and exploratory endpoints

But key secondary and exploratory endpoints from both studies would be expected sometime in the first quarter of 2020, it said.

Acasti also highlighted that assuming the primary endpoint reaches statistical significance in TRILOGY 2, it may still have a path forward to file an NDA (new drug application).

It would seek a meeting with the FDA as soon as possible to discuss all of the TRILOGY data, investigational findings, and obtain its input and guidance on the next steps, it added.

Results showed a 30.5% and 36.7% reduction in triglyceride levels, compared with baseline, among patients receiving CaPre at 12 and 26 weeks respectively.

There was also a 42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks.

Contact the author at [giles@proactiveinvestors.com](mailto:giles@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).